The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.
 
Roisin M. Connolly
Research Funding - Clovis Oncology (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - Syndax
 
Jeffrey P. Leal
No Relationships to Disclose
 
Lilja Solnes
Research Funding - Endocyte
 
Chiung-Yu Huang
No Relationships to Disclose
 
Ashley Carpenter
No Relationships to Disclose
 
Katy Gaffney
No Relationships to Disclose
 
Vandana Gupta Abramson
Consulting or Advisory Role - Novartis
Research Funding - Astellas Pharma; Genentech/Roche
 
Lisa A. Carey
Research Funding - Genentech/Roche (Inst); Innocrin Pharma (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
 
Minetta C. Liu
Research Funding - Eisai (Inst); GRAIL (Inst); Janssen Diagnostics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Agena Bioscience; Celgene; Cynvenio Biosystems; GRAIL; Menarini Silicon Biosystems; Merck
 
Mothaffar F. Rimawi
Consulting or Advisory Role - Celgene
 
Jennifer M. Specht
Consulting or Advisory Role - Abbvie; Advaxis; Celgene
Research Funding - Abbvie (Inst); Cascadian Therapeutics (Inst); Celgene (Inst); Celldex (Inst); Genentech/Roche (Inst); Juno Therapeutics (Inst); Merck (Inst); Myriad Pharmaceuticals (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Anna Maria Storniolo
Employment - Boston Pharmaceuticals (I)
Leadership - Boston Pharmaceuticals (I)
Stock and Other Ownership Interests - Amgen (I); Flexion Therapeutics (I)
Consulting or Advisory Role - Bridge Medicines (I); Lilly
Research Funding - Medivation
 
Vicente Valero
No Relationships to Disclose
 
Christos Vaklavas
Research Funding - Incyte (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Other Relationship - Genentech (I)
 
Melissa Camp
No Relationships to Disclose
 
Robert S. Miller
No Relationships to Disclose
 
Antonio C. Wolff
Research Funding - Myriad Genetics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Ashley Cimino-Mathews
Research Funding - BMS Brazil (Inst)
 
Richard L. Wahl
Honoraria - Cellectar
Consulting or Advisory Role - Nihon Medi-Physics
Research Funding - Actinium Pharmaceuticals (Inst); cyclomedica (Inst); GlaxoSmithKline (Inst); Progenics (Inst); Siemens Healthcare Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from patents on radioimmunotherapy of non-Hodgkins Lymphoma. Paid by GSK and by Spectrum Pharmaceuticals related to the drugs "Bexxar" and "Zevalin".
 
Vered Stearns
Research Funding - Abbvie; MedImmune; Novartis; Pfizer; Puma Biotechnology